Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
8657932 | Chest | 2018 | 90 Pages |
Abstract
To date, randomized studies on treatment outcome in patients with MAC PD are scarce. Long-term treatments with ATS-recommended regimens for patients who are macrolide susceptible are superior to other macrolide-based therapies. A standardized definition of treatment success and genotypic distinction between reinfection and relapse by means of pretreatment and posttreatment identification of MAC species in cases of microbiologic recurrences may help to optimize evaluation of treatment regimens in the future.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Cardiology and Cardiovascular Medicine
Authors
Roland MD, MPH, Albert MD, PhD, Felix C. MD, PhD, Elvira PhD, Tobias MD, PhD, Klaus F. MD, PhD, Robert MD, PhD,